TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04975347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: One bolus and one infusion of naloxone
Study: NCT04668274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg resveratrol as JOTROL
Description: Low (first) dose of single ascending dose study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol as JOTROL
Description: Second (intermediate) dose of single ascending dose study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg resveratrol as JOTROL
Description: Third (highest) dose of single ascending dose study
Study: NCT05414799

Intervention type: OTHER
Group type: OTHER
Intervention: figure eight vision exercise
Description: figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: figure eight vision exercise
Description: figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chin nodding
Description: chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
Study: NCT04668274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol as JOTROL administered to assess influence of food
Description: 500 mg resveratrol as JOTROL administered to assess influence of food
Study: NCT05414799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neck stretching
Description: trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides.
Study: NCT05450211

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)
Description: A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Patient-controlled analgesia will be used for pain control after surgery in both groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Patient-controlled analgesia will be used for pain control after surgery in both groups.
Study: NCT05727436

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dissolve the tablets in the mouth once a day for 4 weeks
Study: NCT04372953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP)
Description: PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive End-Expiratory Pressure (PEEP)
Description: PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).
Study: NCT06298734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Program
Description: A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Program
Description: A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
Study: NCT06564597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
Study: NCT05337566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill + Cefuroxime
Description: Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Cefuroxime
Description: Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Study: NCT06166433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke-free homes intervention
Description: Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
Study: NCT05704387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized GDFT
Description: In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy strategy
Description: from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
Study: NCT06464991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equecabtagene Autoleucel Injection
Description: dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
Study: NCT05121350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin can inhibit the synthesis of DNA and RNA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin can inhibit the synthesis of DNA and RNA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arotinib hydrochloride capsule placebo
Description: Placebo of Anlotinib hydrochloride capsule
Study: NCT04594811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection.
Study: NCT05929313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrbusNeich Scoreflex TRIO
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OrbusNeich Scoreflex NC
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
Study: NCT05576649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task difficulty adaptation according to Arvaneh et al. (2019)
Description: The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Random task difficulty
Description: The task difficulty in the P300 speller training is chosen randomly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task difficulty adaptation according to iterative learning controller
Description: The task difficulty in the P300 speller is determined by an iterative learning controller.
Study: NCT05972018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
Study: NCT05990231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab combined Anlotinib
Description: Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
Study: NCT06217796

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MydCombi
Description: A single metered spray administered with the MydCombi dispenser
Study: NCT04594811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) injection.
Study: NCT04742257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator® device
Description: Trans-spinal DCS paired with peripheral DCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoRegulator® device
Description: Trans-spinal DCS paired with peripheral DCS
Study: NCT04817956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker
Study: NCT05991167

Intervention type: DEVICE
Intervention: EndeavorRx
Description: EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Study: NCT04817956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker
Study: NCT05362851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC301-1 & YYC301-2 & YYC301-3
Description: YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC301 placebo & Celecoxib 200mg
Description: comparator medication
Study: NCT04817956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker
Study: NCT06040398

Intervention type: BEHAVIORAL
Intervention: JUMPSTART exercise program
Description: The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
Study: NCT05525390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Reality-Enhanced Behavioral Activation
Description: Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Behavioral Activation
Description: Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
Study: NCT05603637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation using SmartTouch radiofrequency ablation catheter
Description: Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation using Farawave pulsed-field ablation catheter
Description: Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
Study: NCT04928547

Intervention type: DIAGNOSTIC_TEST
Intervention: Test
Description: Different test

Intervention type: DIAGNOSTIC_TEST
Intervention: Test
Description: Different test
Study: NCT05337189

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine DNA methylation analysis
Description: Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine DNA methylation analysis
Description: Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

Intervention type: PROCEDURE
Intervention: medical imaging and/or cystoscopy and/or pathological examination
Description: Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination

Intervention type: PROCEDURE
Intervention: medical imaging and/or cystoscopy and/or pathological examination
Description: Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
Study: NCT05721651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+PD-1
Description: This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;
Study: NCT04980781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t)
Description: Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation program for PED-t in ERC
Description: Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
Study: NCT06005571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: composite restoration repair by traditional acid etch treatment procedure and adhesive.
Description: Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite restoration repair by acid etching, silane solution application, and then adhesive.
Description: Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.
Description: Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
Study: NCT06097169

Intervention type: DRUG
Intervention: Fentanyl
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.